
ASPO 2025: Advancements in Cancer Prevention Research Methods
Meeting Program
The 2025 Program Committee has been working hard on programming for our 2025 Annual Meeting. Here’s what to expect:
- Four symposia
- Four “Looking Back, Thinking Forward” sessions
- sessions include a 15-minute presentation by a senior scientist, followed by three short presentations selected from submitted abstracts, as well as time for questions/discussion
- “Best of ASPO” sessions
- 32 high-ranking abstracts to be selected for 15-minute oral presentations.
- An invited keynote speaker
- Dr. Richard Wender is the Robert G. Dunlop Professor and Chair of the Department of Family Medicine and Community Health in the Perelman School of Medicine at the University of Pennsylvania.
- Dr. Wender has dedicated his career to leading medical and public health efforts that strive to improve the quality of primary care, implement population health, and address social determinants of health in the continuous pursuit of equity for all people.
- During his keynote speech, Dr. Wender will share with us the “Seven Trends That Will Determine the Future of Cancer Control”.
- Award lectures
- SIG Breakfast Sessions
- Networking lunch
- 2 poster sessions
FAQ
Who attends the ASPO meeting?
Both ASPO members and non-members are encouraged to attend the meeting. Attendees include students, research partners, community advocates/patient advocates, post-doctoral researchers, and faculty/staff members.
What is included in meeting registration?
Registration for the meeting includes access to four symposia and four “Looking Back, Thinking Forward” sessions. The “Looking Back, Thinking Forward” sessions include a 15-minute presentation by a senior scientist, followed by three short presentations selected from submitted abstracts, as well as time for questions/discussion. The “Best of ASPO” sessions allow for 32 high-ranking abstracts to be selected for 15-minute oral presentations. We also have an invited keynote presentation, two award lectures, four to six Special Interest Group breakfast sessions, and a networking lunch.
Your registration includes breakfast & lunch on Monday & Tuesday, as well as light receptions on Sunday & Monday evenings.
Why should I come to the ASPO meeting?
For students and early career researchers, ASPO places a priority on training sessions for early career members to encourage diverse new scientists to enter the field and to assist in their professional development.
A unique aspect of ASPO’s Annual Meetings is driven by its strong ties to NCI and the American Cancer Society due to its focus on the full breadth of cancer prevention and control. Sessions frequently underscore transdisciplinary interaction, an important theme of ASPO, facilitated by the multidisciplinary nature of ASPO meetings
What accessibility related accommodations will be available?
ASPO is committed to ensuring that our event is as accessible as possible for all attendees. We strive to provide a variety of accommodations for individuals with disabilities or other accessibility needs. Please make us aware of your requests on the registration form, or email us at [email protected].
Advertisers, Sponsors, & Exhibitors
There are a variety of opportunities for advertisers, sponsors, and exhibitors for the 2025 Annual Meeting.
2025 Program Committee
Co-Chairs

Carolyn Heckman, PhD
Rutgers Cancer Institute

Karen Wernli, PhD
Kaiser Permanente Washington Health Research Institute
Committee Members
Dejana Braithwaite, PhD, MSc, University of Florida
Albert Farias, PhD, MPH, University of Southern California
Jessica Faupel-Badger, PhD, MPH, National Cancer Institute
Maria Eulalia Fernandez, PhD, UTHealth Houston SPH
Alison Herrmann, PhD, MS, UCLA
Anita Kinney, PhD, RN, Rutgers Cancer Institute
Lorna McNeill, PhD, MPH, UT MD Anderson Cancer Center
Suzanne O’Neill, PhD, Lombardi Cancer Center
Electra Paskett, PhD, The Ohio State University
Michael Scheurer, PhD, MPH, Baylor College of Medicine
Margaux Stack-Babich, MPH, UC San Diego
Parisa Tehranifar, DrPH, Columbia University
K. ‘Vish’ Viswanath, PhD, Dana Farber Cancer Institute
Shaneda Warren Andersen, PhD, University of Wisconsin-Madison
Nur Zeinomar, PhD, MPH, Rutgers Cancer Institute